keyword
MENU ▼
Read by QxMD icon Read
search

Silodosin

keyword
https://www.readbyqxmd.com/read/28627033/silodosin-versus-naftopidil-in-the-treatment-of-premature-ejaculation-a-prospective-multicenter-trial
#1
Yoshikazu Sato, Toshikazu Otani, Toshiyasu Amano, Tohru Araki, Nobuyuki Kondou, Masanori Matsukawa, Musashi Tobe, Kazunori Haga, Kousuke Uchida, Ichiya Honma
OBJECTIVES: To determine the efficacy of two α1-adrenoceptor antagonists with different affinities for α1-adrenoceptor subtypes, silodosin and naftopidil, in the treatment of premature ejaculation. METHODS: This was a prospective, open-label, multicenter trial. A total of 26 patients with untreated acquired premature ejaculation were enrolled. Premature ejaculation was defined based on the International Society for Sexual Medicine recommendation. Patients self-administered on demand silodosin 4 mg or naftopidil 25 mg 1 h before intercourse, alternating drugs at least three times each...
June 18, 2017: International Journal of Urology: Official Journal of the Japanese Urological Association
https://www.readbyqxmd.com/read/28601233/computed-tomography-findings-predicting-the-success-of-silodosin-for-medical-expulsive-therapy-of-ureteral-stones
#2
Serdar Celik, Firat Akdeniz, Muge Afsar Yildirim, Ozan Bozkurt, Merve Gursoy Bulut, Mehmet Levent Hacihasanoglu, Omer Demir
Aim of the study is to investigate the relationship between non-contrast computed tomography (NCCT) findings and stone expulsion rate with medical expulsive therapy (MET) using silodosin for ureteral stones in male adults. Between January 2014 and June 2015, we retrospectively reviewed the patient charts with uncomplicated ureteral stones on NCCT images, who were treated with silodosin for MET. Stone diameter, volume and hounsfield units (HU) measured by NCCT and treatment findings were noted at the end of treatment...
June 2017: Kaohsiung Journal of Medical Sciences
https://www.readbyqxmd.com/read/28569366/the-water-avoidance-stress-induces-bladder-pain-due-to-a-prolonged-alpha1a-adrenoceptor-stimulation
#3
Rita Matos, Paula Serrão, Larissa Rodriguez, Lori Ann Birder, Francisco Cruz, Ana Charrua
Bladder Pain Syndrome/Interstitial Cystitis (BPS/IC) remains an elusive disease with the cause for the pain unclear. BPS/IC patients present increased sympathetic activity and high levels of urinary noradrenaline. At the experimental level, it has been shown that chronic adrenergic stimulation produces pain and bladder changes through an alpha 1A adrenoceptor mediated mechanism. Water avoidance stress (WAS) in rodents reproduces signs of nociception and bladder changes seen in BPS/IC patients. In this study, we explore the possible role of alpha 1A adrenoceptor in bladder pain and morphological changes...
May 31, 2017: Naunyn-Schmiedeberg's Archives of Pharmacology
https://www.readbyqxmd.com/read/28499730/effects-of-withdrawing-alpha-1-blocker-from-the-combination-therapy-with-alpha-1-blocker-and-5-alpha-reductase-inhibitor-in-patients-with-lower-urinary-tract-symptoms-suggestive-of-benign-prostatic-hyperplasia-a-prospective-and-comparative-trial-using-urodynamics
#4
Yoshihisa Matsukawa, Shun Takai, Yasuhito Funahashi, Tsuyoshi Majima, Masashi Kato, Tokunori Yamamoto, Momokazu Gotoh
PURPOSE: To compare the effects on lower urinary tract symptoms (LUTS) and bladder outlet obstruction between combination therapy with α1 blocker and 5α-reductase inhibitor and a switch to 5α-reductase inhibitor monotherapy, and determine the factors influencing changes in LUTS after α1 blocker withdrawal. MATERIALS AND METHODS: One-hundred and forty outpatients with LUTS suggestive of benign prostatic hyperplasia received combination therapy with silodosin 8 mg/day and dutasteride 0...
May 9, 2017: Journal of Urology
https://www.readbyqxmd.com/read/28439987/comparison-of-silodosin-versus-tadalafil-in-patients-with-lower-urinary-tract-symptoms-associated-with-benign-prostatic-hyperplasia
#5
Masaki Yoshida, Hideki Origasa, Narihito Seki
OBJECTIVES: To compare the efficacy and safety of silodosin versus tadalafil for treating lower urinary tract symptoms associated with benign prostatic hyperplasia (LUTS/BPH). METHODS: After informed consent, patients with LUTS/BPH were randomized in a 1:1 ratio to receive silodosin 8 mg/day or tadalafil 5 mg/day for 8 weeks (Period 1). Patients treated with tadalafil entered an exploratory phase and received silodosin or tadalafil for another 8 weeks. The primary efficacy endpoint was the change in the total International Prostate Symptom Score (IPSS) with Period 1 treatment...
April 25, 2017: Lower Urinary Tract Symptoms
https://www.readbyqxmd.com/read/28431996/comparison-of-silodosin-monotherapy-versus-silodosin-with-tadalafil-add-on-therapy-in-patients-with-benign-prostatic-hyperplasia
#6
Takashi Yoshida, Hidefumi Kinoshita, Seiji Shimada, Makoto Taguchi, Tadashi Matsuda
OBJECTIVE: To evaluate the efficacy and safety of add-on therapy with the phosphodiesterase type 5 inhibitor tadalafil for patients with lower urinary tract symptoms secondary to benign prostatic hyperplasia (LUTS/BPH) treated with the α1-adrenoceptor blocker silodosin. METHODS: We analyzed 103 patients with LUTS/BPH with an International Prostate Symptom Score (IPSS) of >8 after ≥4 weeks of silodosin treatment from April 2016 through December 2016 at Kori Hospital...
April 18, 2017: Urology
https://www.readbyqxmd.com/read/28403592/comparison-of-transurethral-incision-of-the-prostate-and-silodosin-in-patients-having-benign-prostatic-obstruction-in-terms-of-retrograde-ejaculation
#7
Basri Cakiroglu, Aydin Ismet Hazar, Orhun Sinanoglu, Ersan Arda, Sinan Ekici
BACKGROUND: To compare the functional outcomes and retrograde ejaculation (RE) after transurethral incision of the prostate (TUIP) or silodosin in bladder outlet obstruction (BOO) secondary to a small prostate. METHODS: Prospectively collected data from December 2011 through December 2014 of 192 LUTS patients having fertility concerns with prostate volume smaller than 40 ml receiving either TUIP or silodosin treatment were prospectively reviewed. The treatment outcomes were evaluated and compared...
March 31, 2017: Archivio Italiano di Urologia, Andrologia
https://www.readbyqxmd.com/read/28394493/synergic-suppressive-effect-of-silodosin-and-imidafenacin-on-non-voiding-bladder-contractions-in-male-rats-with-subacute-bladder-outlet-obstruction
#8
Rino Sugiyama, Naoki Aizawa, Hiroki Ito, Tetsuya Fujimura, Motofumi Suzuki, Tohru Nakagawa, Hiroshi Fukuhara, Haruki Kume, Yukio Homma, Yasuhiko Igawa
OBJECTIVES: To investigate single or combined effect of silodosin, an α1A-adrenoceptor antagonist, and imidafenacin, an antimuscarinic agent, on bladder function in a subacute bladder outlet obstruction (BOO) model of male rats. METHODS: Partial BOO was created in male Wistar rats by ligating the urethra with a steel rod. On day 10 after surgery, when frequent voiding was most remarkable on voiding behavior measurement in a metabolic cage, cystometric investigations in a conscious restrained condition were conducted with cumulative intravenous administration of silodosin alone (0...
May 2017: Lower Urinary Tract Symptoms
https://www.readbyqxmd.com/read/28370420/editorial-comment-to-intravesical-prostatic-protrusion-can-predict-therapeutic-response-to-silodosin-in-male-patients-with-lower-urinary-tract-symptoms
#9
Keong Tatt Foo
No abstract text is available yet for this article.
June 2017: International Journal of Urology: Official Journal of the Japanese Urological Association
https://www.readbyqxmd.com/read/28370376/intravesical-prostatic-protrusion-can-predict-therapeutic-response-to-silodosin-in-male-patients-with-lower-urinary-tract-symptoms
#10
Yoshihisa Matsukawa, Shohei Ishida, Tsuyoshi Majima, Yasuhito Funahashi, Naoto Sassa, Masashi Kato, Yasushi Yoshino, Momokazu Gotoh
OBJECTIVES: To investigate the predicting factors of therapeutic response to α1-blockers in patients with lower urinary tract symptoms associated with benign prostate enlargement based on a urodynamic study. METHODS: This was a prospective study involving 125 outpatients with lower urinary tract symptoms associated with benign prostate enlargement. They received 8 mg of silodosin for 12 months. International Prostate Symptom Score, Overactive Bladder Symptom Score, International Prostate Symptom Score quality of life assessment, and urodynamic study were used to assess subjective and objective symptoms...
June 2017: International Journal of Urology: Official Journal of the Japanese Urological Association
https://www.readbyqxmd.com/read/28365782/role-of-silodosin-as-medical-expulsive-therapy-in-ureteral-calculi-a-meta-analysis-of-randomized-controlled-trials
#11
Xin-Jian Liu, Jian-Guo Wen, You-Dong Wan, Bo-Wen Hu, Qing-Wei Wang, Yan Wang
The objective of this study is to investigate the efficacy of silodosin in medical expulsive therapy (MET) for ureteral stones. We conducted a systematic review and meta-analysis to determine the efficacy and safety of silodosin in MET for ureteral calculi. We searched PubMed, Embase, Medline, Central (the Cochrane Library, Issue 1,2013), Google Scholar from the inception to March 2015 for randomized controlled trials (RCTs), comparing silodosin with tamsulosin or control on ureteral stone passage. Eight RCTs with a total of 1145 ureteral stone patients (300 patients in the control group, 287 patients in the tamsulosin group, 558 patients in the silodosin group) were included in this meta-analysis...
April 1, 2017: Urolithiasis
https://www.readbyqxmd.com/read/28365198/-how-to-act-when-an-alpha-blocker-is-associated-with-a-potent-inhibitor-of-cyp3a4
#12
N Bensalah, S Garcia, F X Rose, P Bedouch, O Conort, M Juste, R Roubille, B Allenet, M Tod, B Charpiat
OBJECTIVE: Combination of alpha-blockers with potent CYP3A4 inhibitors is either contra-indicated or not recommended. We searched data supporting this classification and guiding prescribers when such an interaction occurs. METHODS: We analyzed reports published by the French agency for drug safety, reference books and performed search in databases of pharmacokinetics studies and case or case series related with these interactions. RESULTS: The classification of the potential severity of these interactions defined by the French agency for drug safety evolved over time...
March 29, 2017: Progrès en Urologie
https://www.readbyqxmd.com/read/28255867/benign-prostatic-obstruction-relief-in-patients-with-lower-urinary-tract-symptoms-suggestive-of-benign-prostatic-enlargement-undergoing-endoscopic-surgical-procedures-or-therapy-with-alpha-blockers-a-review-of-urodynamic-studies
#13
REVIEW
Ferdinando Fusco, Massimiliano Creta, Vittorio Imperatore, Nicola Longo, Ciro Imbimbo, Herbert Lepor, Vincenzo Mirone
Benign prostatic obstruction (BPO) contributes to the genesis of lower urinary tract symptoms as well as to pathologic remodeling of the lower and upper urinary tract in patients with benign prostate enlargement. Urodynamic studies demonstrate that both medical therapy with alpha-blockers (ABs) and endoscopic surgical procedures provide BPO relief. However, the magnitude of improvement is higher after surgery. Among ABs, silodosin is associated with the highest improvement of bladder outlet obstruction index (BOOI)...
March 2, 2017: Advances in Therapy
https://www.readbyqxmd.com/read/28116737/efficacy-of-silodosin-dose-in-medical-expulsive-therapy-for-distal-ureteral-stones-a-retrospective-study
#14
Cem Nedim Yuceturk, Mumtaz Dadali, Muhammed Sahin Bagbanci, Berat Cem Ozgur, Yasin Aydogmus, Yildiray Yildiz, Muhammet Fatih Kilinc
PURPOSE: We aimed to investigate the efficacy of silodosin 4 mg/day and 8 mg/day for medical expulsive therapy(MET) of lower ureteral stones. MATERIALS AND METHODS: We retrospectively analyzed the medical records of 161 patients admitted to urologyclinics of Ahi Evran University Medical Faculty and Ankara Training and Research Hospital with distal ureteralstones and treated with MET with different doses of silodosin between January 2013 and August 2015. 81 patientswere treated with silodosin 4mg/day in group-1 and 80 patients with silodosin 8mg/day in group-2...
January 18, 2017: Urology Journal
https://www.readbyqxmd.com/read/28063187/characterization-of-degradation-products-of-silodosin-under-stress-conditions-by-liquid-chromatography-fourier-transform-mass-spectrometry
#15
Sukanya Pandeti, Tadigoppula Narender, Sripadi Prabhakar, Thota Jagadeswar Reddy
RATIONALE: Silodosin (SDN) is a novel α1 -adrenoceptor antagonist in the treatment of benign prostatic hyperplasia (BPH). The presence of degradation products in a drug affects not only the quality, but also the safety and efficacy of drug formulation. Thus, it is essential to develop an efficient analytical method which could be useful to selectively separate, identify and characterise of all possible degradation products of SDN which is mandatory in drug development processes. METHODS: SDN was subjected to forced degradation under hydrolytic (acid, base and neutral), oxidative, photolytic and thermal stress conditions...
March 30, 2017: Rapid Communications in Mass Spectrometry: RCM
https://www.readbyqxmd.com/read/28042309/the-link-between-vascular-dysfunction-bladder-ischemia-and-aging-bladder-dysfunction
#16
REVIEW
Karl-Erik Andersson, Donna B Boedtkjer, Axel Forman
The vascular supply to the human bladder is derived mainly from the superior and inferior vesical arteries, the latter being directly connected to the internal iliac artery. Aging is associated with an impairment of blood vessel function and changes may occur in the vasculature at the molecular, cellular and functional level. Pelvic arterial insufficiency may play an important role in the development of bladder dysfunctions such as detrusor overactivity (DO) and the overactive bladder syndrome. Chronic ischemia-related bladder dysfunction may progress to bladder underactivity and it would be desirable to treat not only lower urinary tract symptoms (LUTS) induced by chronic ischemia, but also the progression of the morphological bladder changes...
January 2017: Therapeutic Advances in Urology
https://www.readbyqxmd.com/read/27889014/-the-role-of-alpha-blockers-in-the-treatment-of-lower-urinary-tract-symptoms-benign-prostatic-hyperplasia-are-all-the-same-silodosin-in-real-life
#17
A Alcántara Montero
The lower urinary tract symptoms (LUTS) are very common in men, particularly in people over 65 years. Benign prostatic hyperplasia (BPH) is the pathology most associated with LUTS in males, and is a common cause of impaired quality of life. Alpha blockers monotherapy represent the treatment of choice in patients with moderate-severe LUTS secondary to BPH. Silodosin is currently the most α1A uroselective alpha blocker, uroselectivity which has been confirmed in several studies both in vitro and in vivo. In this paper the main benefits of silodosin are analyzed in both phase III clinical trials (standard approach) as in "real life" (analyzing the study SiRE [Silodosin in Real-life Evaluation], phase IV study), to validate the test data recording and confirm the positive benefit-risk profile of silodosin in a context that can reflect more closely the clinical practice...
July 2016: Semergen
https://www.readbyqxmd.com/read/27866053/lc-esi-ms-ms-evaluation-of-forced-degradation-behaviour-of-silodosin-in-vitro-anti-cancer-activity-evaluation-of-silodosin-and-major-degradation-products
#18
Chiguru Vishnuvardhan, Baikadi Saibaba, Lingesh Allakonda, Debasish Swain, S Gananadhamu, R Srinivas, N Satheeshkumar
Silodosin (SLD) a novel α1-adrenoceptor antagonist was subjected to forced degradation involving hydrolysis (acidic, alkaline and neutral), oxidative, photolysis and thermal stress, as per ICH specified conditions. The drug underwent significant degradation under hydrolytic (acidic, alkaline and neutral) and oxidative stress conditions whereas, it was found to be stable under other stress conditions. A rapid, precise, accurate and robust chromatographic method for the separation of the drug and its degradation products (DPs) was developed on a Fortis C18 analytical column (150×4...
February 5, 2017: Journal of Pharmaceutical and Biomedical Analysis
https://www.readbyqxmd.com/read/27864702/selective-spectrofluorimetric-method-with-enhanced-sensitivity-for-determination-of-silodosine-in-dosage-form-and-human-plasma-application-to-stability-studies-and-content-uniformity-testing
#19
Mahmoud A Omar, Abdel-Maaboud I Mohamed, Sayed M Derayea, Mohamed A Hammad, Abobakr A Mohamed
A novel, sensitive and selective spectrofluorimetric method has been developed and validated for determination of silodosine (SLD) in its dosage form and human plasma. The method is based on nucleophilic substitution reaction of SLD with 5-(dimethylamino) naphthalene-1-sulfonyl chloride (dansyl chloride) in presence of 5.0 × 10(-4) M sodium carbonate (pH 10.50) to yield a highly fluorescent derivative that was measured at 435 nm after excitation at 347 nm. The different experimental parameters affecting the development and stability of the reaction product were carefully studied and optimized...
November 19, 2016: Journal of Fluorescence
https://www.readbyqxmd.com/read/27864032/%C3%AE-1a-adrenergic-receptor-antagonism-improves-erectile-and-cavernosal-responses-in-rats-with-cavernous-nerve-injury-and-enhances-neurogenic-responses-in-human-corpus-cavernosum-from-patients-with%C3%A2-erectile-dysfunction-secondary-to-radical-prostatectomy
#20
Juan I Martínez-Salamanca, José M La Fuente, Eduardo Martínez-Salamanca, Argentina Fernández, Augusto J Pepe-Cardoso, Nuno Louro, Joaquín Carballido, Javier Angulo
INTRODUCTION: Cavernous nerve injury (CNI) in rats and radical prostatectomy (RP) in men result in loss of nitrergic function and increased adrenergic-neurogenic contractions of cavernosal tissue. AIM: To evaluate the modulation of the α-adrenergic system as a strategy to relieve erectile dysfunction (ED) and functional cavernosal alterations induced by CNI. METHODS: A non-selective α-blocker (phentolamine 1 mg/kg daily), a selective α1A-blocker (silodosin [SILOD] 0...
December 2016: Journal of Sexual Medicine
keyword
keyword
105114
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"